Repurposing antimalarial aminoquinolines and related compounds for treatment of retinal neovascularization.

ABSTRACT: Neovascularization is the pathological driver of blinding eye diseases such as retinopathy of prematurity, proliferative diabetic retinopathy, and wet age-related macular degeneration. The loss of vision resulting from these diseases significantly impacts the productivity and quality of life of patients, and represents a substantial burden on the health care system. Current standard of care includes biologics that target vascular endothelial growth factor (VEGF), a key mediator of neovascularization. While anti-VGEF therapies have been successful, up to 30% of patients are non-responsive. Therefore, there is a need for new therapeutic targets, and small molecule inhibitors of angiogenesis to complement existing treatments. Apelin and its receptor have recently been shown to play a key role

SUBMITTER: McAnally D 

PROVIDER: S-EPMC6135396 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature